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 24 
Abstract 25 
 Medical device-associated infections caused by Staphylococcus 26 
epidermidis usually involve biofilm formation and its eradication is 27 
particularly challenging. Although rifampicin has been proving to be one of 28 
the most effective antibiotics against S. epidermidis biofilms its use as a 29 
single agent can lead to the acquisition of resistance. Therefore, we 30 
assessed the combined effect of rifampicin with N-acetylcysteine (NAC) 31 
known by its mucolytic effect, in the control of S. epidermidis biofilms. 32 
Biofilms of two S. epidermidis strains (9142 and 1457) were treated with 33 
1xMIC (4 mg/mL) and 10xMIC (40 mg/mL) of NAC and 10 mg/L (peak 34 
serum) of rifampicin alone and in combination. NAC at 40 mg/L alone or in 35 
combination with rifampicin (10 mg/L) significantly reduced (4 log10) the 36 
number of biofilm cells. Considering their different modes of action, the 37 
association of NAC with rifampicin constitutes a promising therapeutic 38 
strategy in the treatment of infections associated to S. epidermidis 39 
biofilms. 40 
 41 
 42 
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 47 
INTRODUCTION 48 
Staphylococcus epidermidis and other coagulase-negative 49 
staphylococci (CoNS) produce extracellular matrix, which is an important 50 
virulence factor. This polymeric matrix promotes bacterial adhesion and 51 
produces a bioﬁlm that makes the eradication of microorganisms more 52 
difficult (1). Staphylococcus epidermidis, the most frequently isolated 53 
coagulase-negative staphylococcus, is the leading cause of infection 54 
related to implanted medical devices (IMDs). This is directly related to its 55 
capability to establish multilayered, highly structured biofilms on artificial 56 
surfaces. Bacterial biofilms are difficult to detect in routine diagnostics and 57 
are inherently tolerant to host defenses and conventional antibiotic 58 
therapies. Thus, device-related infections are notoriously difficult to treat 59 
and bacteria within biofilm communities on the surface of IMDs frequently 60 
outlive treatment, and removal of the medical device is often required for 61 
successful therapy (2). Additionally, the emergence of antibiotic-resistant 62 
bacteria and the slow progress in identifying new classes of antimicrobial 63 
agents have encouraged research into novel therapeutic strategies (3). 64 
N-acetylcysteine (NAC) is a non-antibiotic drug that has antibacterial 65 
properties. It is a mucolytic agent that disrupts disulphide bonds in mucus 66 
and reduces the viscosity of secretions (4). NAC is commonly used in 67 
medical treatment of chronic bronchitis and cancer (5, 6) and is one of the 68 
smallest drug molecules in use (7). NAC affects several processes that are 69 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
4 
 
important for bacterial biofilm formation on stainless steel surfaces, 70 
including a drastic reduction in extracellular polysaccharide production, 71 
and thus acts as an antibiofilm substance (8).  72 
Previous results have demonstrated that rifampicin is the most 73 
effective of traditional antibiotics against S. epidermidis cells in biofilms (9-74 
12). 75 
Accordingly, the aim of this work was to determine the in vitro effect 76 
of NAC alone but specifically in combination with rifampicin on biofilms of 77 
two different S. epidermidis strains.  78 
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 93 
MATERIALS AND METHODS 94 
Bacterial strains and growth conditions 95 
Two Staphylococcus epidermidis clinical isolate strains (9142 and 96 
1457, good bioﬁlm-producers) were used in this study. Both strains were 97 
provided by Dr. G. B. Pier, Channing Laboratory, Department of Medicine, 98 
Brigham and Women’s Hospital, Harvard Medical School, Boston, USA.  99 
The culture media used tryptic soy broth (TSB) and tryptic soy agar 100 
(TSA), were prepared according to the manufacturer’s instructions. All 101 
strains were inoculated into 15 mL of TSB from TSA plates not older than 102 
2 days and grown for 24 (±2) h at 37°C in an orbital shaker at 130 rpm. 103 
Cells were harvested by centrifugation (for 5 min at 9500g and 4°C), and 104 
ressuspended in TSB adjusted to an optical density (640 nm) equivalent to 105 
1 x 106 cells/mL and then used in the subsequent assays.  106 
Solutions of NAC 4 mg/mL (1x MIC) and 40 mg/mL (10x MIC) (13) 107 
were prepared in TSB and stock solution of rifampicin (10 mg/L - peak 108 
serum concentration) (9, 14) was prepared in methanol.  109 
 110 
Minimum inhibitory concentration (MIC) 111 
MIC determination of the tested agent N-acetylcysteine and for each 112 
S. epidermidis strain (9142 and 1457) was carried with dilution range of 113 
0.5-64 mg/mL.   114 
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The MIC was determined in 96 well tissue culture plates (Sarstedt, 115 
Newton, NC, USA) containing 100 µL of a stock solution of NAC (64 116 
mg/mL) and the dilution was realized with TSB, adding at the end 100 µL 117 
of a S. epidermidis cell suspension (1 x 106 cells/mL). Plates were 118 
incubated at 37°C with orbital shaking at 130 rpm for 24 h.  After 119 
incubation the minimum inhibitory concentration was determined with the 120 
lowest concentration able to inhibit bacterial growth. 121 
The controls were not exposed to the antimicrobial agent tested. All 122 
experiments were carried out in triplicate and repeated three times. 123 
 124 
Effect of NAC and rifampicin on bioﬁlm cells 125 
Bioﬁlms were formed in 96 well tissue culture plates (Sarstedt, 126 
Newton, NC, USA) containing 200 µL of a S. epidermidis cell suspension 127 
(1 x 106 cells/mL) in TSB supplemented with 0.25% of glucose per well to 128 
promote bioﬁlm formation. Plates were incubated at 37°C with orbital 129 
shaking at 130 rpm for 24 h. At the end, planktonic cells were removed 130 
carefully, and the bioﬁlm was washed twice with 200 µL of saline solution 131 
(0.9% NaCl; Merck). The bioﬁlms were incubated for 24 h in fresh nutrient 132 
medium containing NAC (4 mg/mL and 40 mg/mL) or rifampicin (10 mg/L) 133 
alone or a combination of both NAC concentrations tested with rifampicin.  134 
Crystal violet (CV) staining was used as indicator of total bioﬁlm 135 
biomass. After exposure to the treatment agents, bioﬁlms were washed 136 
with 200 µL of saline solution, then 250 µL of methanol was added and 137 
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allowed to act for 15 min. Afterwards methanol was removed and crystal 138 
violet was added (5 min). The wells were washed with water and ﬁnally, 139 
acetic acid 33% (v/v) was added. The absorbance was measured at 570 140 
nm. 141 
Another colorimetric method based on the reduction of XTT ({2,3-142 
bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phe-nylamino)carbonyl]-2H-143 
tetrazolium hydroxide}; Sigma, St Louis, USA) was applied to determine 144 
cell activity (XTT is converted to a colored formazan salt in the presence of 145 
metabolic activity) (15). After exposure to antimicrobial agents, bioﬁlms 146 
were washed with 200 µL of saline solution, then 200 µL of a solution 147 
containing 200 mg/L of XTT and 20 mg/L of phenazine methosulphate 148 
(PMS; Sigma, St Louis, USA) was added to each well. The microtiter 149 
plates were incubated for 3 h at 37°C in the dark. The absorbance was 150 
measured at 490 nm. 151 
To assess the number of viable cells after treatment, 200 µL of saline 152 
solution were added to each well before removing the biofilm by 153 
scrapping. An aliquot of 1 mL of each sample was centrifuged (for 10 min 154 
at 9500g and 4°C) and the pellet ressuspended in 1 mL of saline solution. 155 
Next, the suspension was sonicated (20 s with 22% of amplitude; 156 
Ultrasonic Processor, Cole-Parmer, Illinois, USA) to promote bioﬁlm 157 
disruption. The number of colony forming units (CFU) in bioﬁlm for each S. 158 
epidermidis strain was determined by performing 10-fold serial dilutions in 159 
saline solution and plating in TSA in triplicate and incubating for 24–48 h. 160 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
8 
 
Biofilm controls were not exposed to any antimicrobial agent tested. 161 
All experiments were carried out in triplicate and repeated three times. 162 
Effect of NAC and rifampicin on planktonic cells 163 
For each strain, 200 μL of a cell suspension adjusted to 1 × 109 164 
cells/mL and 1.5 mL of that suspension was added to 15 mL of TSB until a 165 
cell density of 1 × 108 cells/mL was reached and were then dispensed in 166 
test tubes followed by the addition of the treating agents alone, NAC (4 167 
mg/mL and 40 mg/mL) or rifampicin (10 mg/L), and in combination. All the 168 
tubes were incubated at 37°C with shaking at 130 rpm. 169 
Cell susceptibility to the treatment agents was determined by the 170 
XTT colorimetric method. For that, 1 mL of each sample was collected and 171 
centrifuged (for 10 min at 9500g and 4°C) and the pellet was 172 
ressuspended in 1 mL of saline solution (0.9% NaCl; Merck). From each 173 
suspension, 200 μL were transferred to individual wells of a 96-well 174 
microtiter plate. Then, 50 μL of a solution containing 200 mg/L of XTT and 175 
20 mg/L of PMS were added to each well and the microtiter plates were 176 
incubated for 3 h at 37°C in the dark. The absorbance was measured at 177 
490 nm.  178 
For CFU determination, 1 mL of each sample was collected and 179 
centrifuged (for 10 min at 9500g and 4°C) and the pellet ressuspended in 180 
1 mL of saline solution. The suspension was sonicated (20 s with 22% of 181 
amplitude; Ultrasonic Processor, Cole-Parmer, Illinois, USA) and the 182 
viable planktonic cells were determined by performing 10-fold serial 183 
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dilutions in saline solution and plating in TSA. Colonies were counted after 184 
24-48 h at 37°C.  185 
Controls were planktonic cells not exposed to any treatment agent 186 
tested. All experiments were carried out in triplicate and repeated three 187 
times. 188 
 189 
Extraction of the exopolymeric matrix 190 
Bioﬁlms were formed in 6 well tissue culture plates (Sarstedt, 191 
Newton, NC, USA) containing 4 mL of a S. epidermidis cell suspension (1 192 
x 106 cells/mL) in TSB supplemented with 0.25% of glucose per well to 193 
promote bioﬁlm formation. Plates were incubated at 37°C with orbital 194 
shaking at 130 rpm for 24 h. At the end, planktonic cells were removed 195 
carefully, and the bioﬁlm was washed twice with 4 mL of saline solution. 196 
The bioﬁlms were incubated in fresh nutrient medium containing NAC (4 197 
mg/mL and 40 mg/mL), rifampicin (10 mg/L) alone and NAC in 198 
combination with rifampicin. After 24 h of incubation, the bioﬁlm was 199 
washed twice with 4 mL of saline solution. Next, 4 mL of phosphate 200 
buffered saline (pH 7.0) were added and the biofilm formed was removed 201 
from the well by scrapping with a cell scraper (zellschaber/24 cm). The 202 
samples were centrifuged for 5 min at 9500g and 4°C, and ressuspended 203 
in 5 mL of extraction buffer (2 mM Na3PO4; 4 mM NaH2PO4; 9 mM NaCl 204 
and 1 mM KCl, pH 7.0) and 1 g of resin (Dowex/50X8, Na+ form, 20-50 205 
mesh, Aldrich-Fluka 44445) was added. The samples were incubated at -206 
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5°C for 2 h. After the incubation the samples were centrifuged for 20 min 207 
at 9500g and 4°C.  208 
The polysaccharide content in the biofilm matrix was quantified by 209 
the method of Dubois et al. (16). The protein content of the biofilm matrix 210 
was measured using the BCAtm Protein Assay Kit (Bicinchoninic Acid, 211 
Sigma-Aldrich, St Louis, USA).  212 
Controls were bioﬁlms not exposed to any treatment agent tested. All 213 
experiments were carried out in triplicate and repeated three times. 214 
 215 
Scanning electron microscopy (SEM) 216 
Bioﬁlms formed in 12 well tissue culture plates (Sarstedt, Newton, 217 
NC, USA) were dehydrated by 15 min immersion in increasing ethanol 218 
concentrations (70, 95 and 100% [v/v]), and then placed in a sealed 219 
desiccator. The samples were mounted on aluminum stubs with carbon 220 
tape, sputter coated with gold and observed with a Leica Cambridge S-221 
360 scanning electron microscope (Leo, Cambridge, UK).  222 
Controls were bioﬁlms not exposed to any treatment agent tested. All 223 
experiments were carried out in triplicate. 224 
 225 
Statistical Analysis 226 
The data from all assays were compared using one-way analysis of 227 
variance (ANOVA) by applying Tukey’s test with all calculations carried out 228 
using SPSS software (Statistical Package for the Social Sciences). 229 
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Differences achieving a conﬁdence level of 95% were considered 230 
signiﬁcant. 231 
RESULTS  232 
Figure 1 presents the number of viable cells of the two S. epidermidis 233 
strains tested, expressed as log CFU, remaining after the treatment of 234 
either biofilm or planktonic cells. It can be observed that NAC alone at 4 235 
mg/mL (1x MIC) had a slight inhibitory effect on planktonic cells but almost 236 
no effect on biofilms, while at 10x MIC it showed a notorious killing effect 237 
on planktonic cells (almost total eradication) and a significant bactericidal 238 
effect on biofilms, in this case promoting CFU reductions of about 4 log10 239 
(p<0.05). Rifampicin alone, showed an effect on biofilm cells promoting 240 
CFU reduction of about 3 log10 (p<0.05). Although the reduction promoted 241 
by rifampicin in planktonic cells was less than 3 log. The NAC-rifampicin 242 
combination consistently decreased the number of viable biofilm 243 
associated bacteria by 3-4 log10 independently of NAC concentration used. 244 
In fact, NAC at 40 mg/ml (10x MIC), rifampicin alone or NAC-rifampicin 245 
combinations showed significant but similar bactericidal effect against 246 
biofilms (p<0.05). The combination of NAC (10x MIC) with rifampicin in 247 
planktonic cells promoted a killing effect (p<0.05). 248 
The results expressing the decrease in metabolic activity measured 249 
by the XTT reduction assay after treatment with the tested agents are 250 
showed in figure 2.  251 
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In addition, total biofilm biomass, assessed by CV staining, also 252 
confirms the effect of the agents tested as can be seen in figure 3.   253 
The matrix composition showed a generally significant increase 254 
(p<0.05) in the amount of proteins and polysaccharides after treatment, 255 
presented in figure 4. The amount of proteins was very high after 256 
treatment with the combination NAC 40 mg/mL with rifampicin (p<0.05). 257 
However, the amount of polysaccharides was high after treatment with 258 
NAC (10x MIC) alone or the combination NAC-rifampicin, independently of 259 
NAC concentration used (p<0.05). 260 
Scanning electron microscope images of the biofilms are presented 261 
in figure 5. The SEM shows representative images of S. epidermidis 262 
(strain 1457) biofilms after treatment with the agents tested alone and in 263 
combination. As can be seen (Figure 5C and F), after treatment with NAC 264 
at 40 mg/mL alone or combined with rifampicin the amount of matrix 265 
present is very small and this might be due to an easy removal of the 266 
matrix during the desiccation procedure by successively washing with 267 
increasing ethanol concentrations. 268 
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 274 
 275 
DISCUSSION 276 
Modern medicine is facing the challenge to control the increasing 277 
incidence of biofilm infections and this situation has boosted the search of 278 
new therapeutic strategies able to evade the intrinsic tolerance of biofilms 279 
to antimicrobial agents. Accordingly, the rationale of this study stems from 280 
the reported effect of NAC in disrupting mature biofilms (4) and the high 281 
efficacy of rifampicin against S. epidermidis biofilms when compared with 282 
other common antibiotics (9-12). Thus, we hypothesized that in 283 
combination they could have a synergistic effect due to their different 284 
modes of action. 285 
The great efficacy of NAC against planktonic cells was also 286 
conﬁrmed in experiments with other gram-positive and gram-negative 287 
strains, showing that NAC did indeed reduce the growth of all strains 288 
tested (8). Rifampicin alone, as we could expect from previous studies (9-289 
11), showed higher efficacy against biofilm cells than planktonic cells. As 290 
demonstrated by viable cells reduction (Figure 1) and in opposition to our 291 
hypothesis the combinations tested were not synergistic or additive in 292 
controlling S. epidermidis biofilms. In a previous study (13), reported a 293 
synergistic effect of NAC in combination with tigecycline on S. epidermidis 294 
biofilms using NAC at 20x MIC (80 mg/mL) and tigecycline at 1000x MIC 295 
(1 mg/mL) with the MIC values reporting to planktonic cells. Nevertheless, 296 
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their results in viable cells reduction of this species were less than 3 log10. 297 
Regarding the NAC-rifampicin combination tested herein the values 298 
obtained where higher, corresponding to a bactericidal action, even if not 299 
corresponding to a synergy between the two agents. 300 
In this work, the biofilm formation capability was as well evaluated 301 
through crystal violet, allowing the quantification of the total biomass. The 302 
metabolic activity of biofilms was evaluated through XTT reduction assays. 303 
The results shown are in very good agreement with those obtained in 304 
terms of cell viability. 305 
Interestingly, the matrix composition showed a generally significant 306 
increase in the amount of proteins and polysaccharides after treatment 307 
(Figure 4). Notoriously, the amount of proteins was very high after 308 
treatment, which is consistent with a higher degree of cell lysis. The 309 
increase in polysaccharides content is probably due in greater extent to 310 
the loosening effect of NAC on the matrix structure and thus making its 311 
extraction more efficacious. As shown previously the strain 1457 produces 312 
more extracellular polysaccharides than 9142 (17). Moreover, NAC is a 313 
thiol containing molecule that is described to disrupt disulfide bonds in 314 
mucus (18). In fact, SEM observations support this hypothesis.  315 
It should be stressed that it is now generally accepted that a 316 
combination of antimicrobial agents is a strategy to evade the 317 
development of bacterial resistance to antibiotics. In fact, it is not 318 
advisable to use rifampicin as a single agent to treat infections because of 319 
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the rapid selection of resistant mutants (19). Zheng and Stewart (20) 320 
detected rifampicin-resistant mutants, when colony biofilms were exposed 321 
to rifampicin for periods longer than 48 h. In the present case, the 322 
combination 40 mg/mL NAC- 10 mg/L rifampicin showed a higher and real 323 
bactericidal effect on biofilms (above 3 log10), which probably opens the 324 
way for an efficient action of the immune system in the eradication of in 325 
vivo biofilms. 326 
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 434 
 435 
LEGEND TO FIGURES 436 
 437 
Figure 1. Number of viable cells (expressed as log10 CFU) of S. 438 
epidermidis recovered from biofilm cells (A) and planktonic cells (B) after 439 
treatment with NAC and rifampicin (RIF) alone or in combination. 440 
 441 
Figure 2. Cellular activity expressed as XTT absorbance of S. 442 
epidermidis biofilm cells (A) and planktonic cells (B) after treatment with 443 
NAC and rifampicin (RIF) alone or in combination. 444 
 445 
Figure 3. S. epidermidis total biofilm biomass expressed as crystal violet 446 
absorbance after treatment with NAC and rifampicin (RIF) alone or in 447 
combination on biofilm cells. 448 
 449 
Figure 4. Quantification of protein (A) and polysaccharides (B) of the 450 
exopolymeric matrix of S. epidermidis (9142 and 1457) biofilms. 451 
 452 
Figure 5. Scanning electron microscopy photographs of 24 h S. 453 
epidermidis (strain 1457) biofilms: control (A), NAC 4 mg/mL (B), NAC 40 454 
mg/mL (C), rifampicin (D), NAC (4 mg/mL) with rifampicin (E) and NAC 455 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
21 
 
(40 mg/mL) with rifampicin (F). The bar in the images corresponds to 456 
5µm. Magnification x 5000. 457 
